Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;11(1):91-98.
doi: 10.1007/s40801-023-00381-3. Epub 2023 Jul 18.

Compliance with Pregnancy Prevention Recommendations for Isotretinoin Following the Amendment of the European Union Pregnancy Prevention Program: A Repeat Study in Estonia

Maaja Ivask  1   2 , Katrin Kurvits  3 , Maia Uusküla  3 , Anne Juppo  4 , Ott Laius  3 , Mia Siven  4   5
Affiliations

Compliance with Pregnancy Prevention Recommendations for Isotretinoin Following the Amendment of the European Union Pregnancy Prevention Program: A Repeat Study in Estonia

Maaja Ivask et al. Drugs Real World Outcomes. 2024 Mar.

Abstract

Background: Isotretinoin, indicated for severe acne, is a potent teratogen and therefore contraindicated in pregnancy. Thus, the pregnancy prevention program (PPP) for isotretinoin has been introduced.

Objectives: The aim of this study was to assess the concomitant use of isotretinoin and effective contraception and the rate of potential isotretinoin-exposed pregnancies in females of childbearing age in 2017-2020 in Estonia. In addition, we aimed to evaluate whether compliance with the PPP has improved compared with the previous study conducted in Estonia covering the period of 2012-2016.

Methods: This retrospective, nationwide study using prescription and healthcare claims data included 2575 females aged 15-45 years who started using isotretinoin between 2017 and 2020.

Results: For 64.7% of females of childbearing age, no concurrent use of an effective contraceptive was detected while using isotretinoin. A moderately higher contraceptive coverage (35.3%) was observed compared with the previous study (29.7%) (p < 0.001). Complete contraception coverage was highest in females aged 30-39 years with an adjusted OR of 12.8 (p < 0.001) compared with the age group 15-19 years and 2.47 (p < 0.001) compared with the age group 20-29 years. 17 pregnancies coincided with the isotretinoin treatment-related period. The risk for potential isotretinoin-exposed pregnancy was 6.6 (95% CI 3.9-10.5) per 1000 treated females of childbearing age over the 4-year observation period. The risk for potential isotretinoin-exposed pregnancies per 1000 treated females was 1.0 in females aged 15-19 years, 11.6 in females aged 20-29 years, 8.8 in females aged 30-39 years, and 7.4 in females aged 40-45 years (p = 0.009).

Conclusion: A slight improvement in complete contraceptive coverage during isotretinoin use has not resulted in a decrease in the risk of isotretinoin-exposed pregnancies. The contraceptive usage and risk for pregnancy vary greatly across age groups, suggesting the need for a more targeted approach to improve the effectiveness of the PPP.

PubMed Disclaimer

Conflict of interest statement

Maaja Ivask is employed as a Patient Safety Lead Estonia, Roche International Pharmacovigilance, Roche Eesti OÜ. Katrin Kurvits, Maia Uusküla, Anne Juppo, Ott Laius, and Mia Siven report no conflict of interest.

Figures

Fig. 1
Fig. 1
Proportion of different contraceptive methods among females of childbearing age who used contraceptives with isotretinoin in Estonia in 2017–2020 by age group
Fig. 2
Fig. 2
Proportion of contraceptive coverage with isotretinoin in females aged 15–45 years in Estonia in 2017–2020 by age group
Fig. 3
Fig. 3
Factors associated with effective contraception coverage with isotretinoin in females aged 15–45 years in Estonia in 2017–2020
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Graber E. Acne vulgaris: overview of management. UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
    1. Rosa FW. Teratogenicity of Isotretinoin. Lancet. 1983;322:513. doi: 10.1016/S0140-6736(83)90538-X. - DOI - PubMed
    1. Lammer EJ, Chen DT, Hoar RM, Agnish ND, Benke PJ, Braun JT, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313:837–841. doi: 10.1056/NEJM198510033131401. - DOI - PubMed
    1. Crijns HJMJ, Straus SM, Gispen-de Wied C, de Jong-van den Berg LTW. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Br J Dermatol [Internet]. 2011;164:238–244. doi: 10.1111/j.1365-2133.2010.09976.x. - DOI - PubMed
    1. Retinoid-containing medicinal products | European Medicines Agency [Internet]. https://www.ema.europa.eu/en/medicines/human/referrals/retinoid-containi.... Accessed 28 Nov 2022.

LinkOut - more resources